Synonym
SR33805; SR-33805; SR 33805;
IUPAC/Chemical Name
N-(3,4-dimethoxyphenethyl)-3-(4-((2-isopropyl-1-methyl-1H-indol-3-yl)sulfonyl)phenoxy)-N-methylpropan-1-amine
InChi Key
OGLMUIRZIMTHMN-UHFFFAOYSA-N
InChi Code
InChI=1S/C32H40N2O5S/c1-23(2)31-32(27-10-7-8-11-28(27)34(31)4)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6/h7-8,10-17,22-23H,9,18-21H2,1-6H3
SMILES Code
O=S(C1=CC=C(OCCCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1)(C3=C(C(C)C)N(C)C4=C3C=CC=C4)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels.
In vivo activity:
This study indicates SR33805 treatment improved contractility of ischaemic failing hearts after myocardial infarction (MI) in rats. Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes. Administration of a single intra-peritoneal bolus of SR33805 improved end-systolic strain and fractional shortening of MI hearts.
Reference: Cardiovasc Res. 2011 Aug 1;91(3):412-9. https://pubmed.ncbi.nlm.nih.gov/21467075/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
564.74
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Ait Mou Y, Toth A, Cassan C, Czuriga D, de Tombe PP, Papp Z, Lacampagne A, Cazorla O. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1;91(3):412-9. doi: 10.1093/cvr/cvr096. Epub 2011 Apr 4. PMID: 21467075; PMCID: PMC3139448.
2. Hainaud P, Bonneau M, Pignaud G, Bal dit Sollier C, André P, Hadjiisky P, Fieffé JP, Caen JP, Herbert JM, Dol F, Drouet LO. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1;154(2):301-8. doi: 10.1016/s0021-9150(00)00487-1. PMID: 11166762.
In vivo protocol:
1. Ait Mou Y, Toth A, Cassan C, Czuriga D, de Tombe PP, Papp Z, Lacampagne A, Cazorla O. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1;91(3):412-9. doi: 10.1093/cvr/cvr096. Epub 2011 Apr 4. PMID: 21467075; PMCID: PMC3139448.
2. Hainaud P, Bonneau M, Pignaud G, Bal dit Sollier C, André P, Hadjiisky P, Fieffé JP, Caen JP, Herbert JM, Dol F, Drouet LO. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1;154(2):301-8. doi: 10.1016/s0021-9150(00)00487-1. PMID: 11166762.
1: Ait Mou Y, Toth A, Cassan C, Czuriga D, de Tombe PP, Papp Z, Lacampagne A, Cazorla O. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1;91(3):412-9. doi: 10.1093/cvr/cvr096. Epub 2011 Apr 4. PMID: 21467075; PMCID: PMC3139448.
2: Cazorla O, Lacampagne A, Fauconnier J, Vassort G. SR33805, a Ca2+ antagonist with length-dependent Ca2+ -sensitizing properties in cardiac myocytes. Br J Pharmacol. 2003 May;139(1):99-108. doi: 10.1038/sj.bjp.0705221. PMID: 12746228; PMCID: PMC1573823.
3: Hainaud P, Bonneau M, Pignaud G, Bal dit Sollier C, André P, Hadjiisky P, Fieffé JP, Caen JP, Herbert JM, Dol F, Drouet LO. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1;154(2):301-8. doi: 10.1016/s0021-9150(00)00487-1. PMID: 11166762.
4: Ieiri S, Hirano K, Nishimura J, Suita S, Kanaide H. Alteration of the [Ca(2+)](i)-force relationship during the vasorelaxation induced by a Ca(2+) channel blocker SR33805 in the porcine coronary artery. Br J Pharmacol. 2000 Dec;131(8):1597-606. doi: 10.1038/sj.bjp.0703721. PMID: 11139437; PMCID: PMC1572486.
5: Melliti K, Bournaud R, Bastide B, Hidalgo J, Shimahara T. Effect of SR33805 on barium current and asymmetric intramembrane charge movement in freshly dissociated mouse cerebellar Purkinje neurons. Neurosci Lett. 1996 Oct 4;216(3):167-70. doi: 10.1016/0304-3940(96)13038-x. PMID: 8897484.
6: Romey G, Lazdunski M. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52. PMID: 7996445.
7: Romey G, Bois P, Lazdunski M. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22;263(1-2):101-5. doi: 10.1016/0014-2999(94)90529-0. PMID: 7821341.
